IRIDEX (IRIX) Expected to Release Quarterly Earnings on Tuesday

IRIDEX (NASDAQ:IRIX) is anticipated to post its Q3 2026 results after the market closes on Tuesday, November 17th. Analysts expect the company to post earnings of ($0.04) per share and revenue of $12.64 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 17, 2026 at 5:00 PM ET.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analyst estimates of $13.59 million.

IRIDEX Trading Up 7.4%

IRIX opened at $0.71 on Tuesday. IRIDEX has a 52-week low of $0.61 and a 52-week high of $1.65. The business’s 50-day simple moving average is $0.71 and its 200 day simple moving average is $1.02.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, IRIDEX currently has a consensus rating of “Hold” and an average target price of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops, manufactures and sells laser-based medical systems and disposable devices used in ophthalmic procedures. Its technologies are designed to help eye-care professionals treat glaucoma, retinal diseases and other conditions affecting vision.

The company’s product portfolio includes the Cyclo Glaucoma Laser System, which uses MicroPulse and continuous-wave laser technology for glaucoma treatment, as well as laser systems such as the IRIDEX IQ series for retinal and photocoagulation procedures.